Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are increasingly used for advanced non-small cell lung cancer (NSCLC) as first-line therapy. The bioavailability and efficacy of oral EGFR-TKIs could be affected by acid suppression (AS) therapy such as PPIs and H2...

Descripción completa

Detalles Bibliográficos
Autores principales: Sim, Wilson, Jain, Sneha Rajiv, Lim, Wen Hui, Chin, Yip Han, Ng, Cheng Han, Syn, Nicholas, Goh, Kang Shiong, Soo, Ross, Wang, Lingzhi, Goh, Boon Cher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435386/
https://www.ncbi.nlm.nih.gov/pubmed/34584857
http://dx.doi.org/10.21037/tlcr-21-378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435386/
https://www.ncbi.nlm.nih.gov/pubmed/34584857
http://dx.doi.org/10.21037/tlcr-21-378

Ejemplares similares